KAYLA DYER: Open Payments
NPI 1992257323 · HUNTSVILLE, AL. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$3,728 in 118 payments from 19 companies in 2025. Trend: 2023 $305 · 2024 $932 · 2025 $3,728
Food & beverage: $3,728
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 41 | $1,415 |
| Janssen Biotech, Inc. | 10 | $485 |
| Madrigal Pharmaceuticals | 8 | $462 |
| Gilead Sciences, Inc. | 7 | $202 |
| Janssen Scientific Affairs, LLC | 2 | $150 |
| Ardelyx, Inc. | 7 | $146 |
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $136 |
| GENZYME CORPORATION | 3 | $126 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 7 | $100 |
| Aimmune Therapeutics, Inc. | 5 | $89 |
Products named: TREMFYA, RINVOQ, REZDIFFRA, SKYRIZI, DUPIXENT, IBSRELA, ENTYVIO, CREON.
Industry payments across AL — which companies pay providers there.
